慢性肾脏疾病-矿物质和骨骼疾病(CKD-MBD),从实验室到床边

K. Nitta, N. Hanafusa, K. Akiyama, Yuki Kawaguchi, Ken Tsuchiya
{"title":"慢性肾脏疾病-矿物质和骨骼疾病(CKD-MBD),从实验室到床边","authors":"K. Nitta, N. Hanafusa, K. Akiyama, Yuki Kawaguchi, Ken Tsuchiya","doi":"10.3390/kidneydial3010004","DOIUrl":null,"url":null,"abstract":"Chronic kidney disease—mineral and bone disorder (CKD-MBD) is a systemic disorder that increases the risk of morbidity and mortality in dialysis patients. CKD-MBD is highly prevalent in dialysis patients, and appropriate treatment is important for improving their outcomes. Inorganic phosphate, fibroblast growth factor 23, parathyroid hormone, and calciprotein particles are markers for critical components and effectors of CKD-MBD, and higher circulating levels of these markers are linked to cardiovascular diseases. In this short review, we focus on the pathogenesis and management of CKD-MBD in CKD patients, especially those on dialysis therapy, and discuss the prospects for improving the management in CKD patients, including those on dialysis.","PeriodicalId":74038,"journal":{"name":"Kidney and dialysis","volume":"21 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Chronic Kidney Disease—Mineral and Bone Disorder (CKD-MBD), from Bench to Bedside\",\"authors\":\"K. Nitta, N. Hanafusa, K. Akiyama, Yuki Kawaguchi, Ken Tsuchiya\",\"doi\":\"10.3390/kidneydial3010004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chronic kidney disease—mineral and bone disorder (CKD-MBD) is a systemic disorder that increases the risk of morbidity and mortality in dialysis patients. CKD-MBD is highly prevalent in dialysis patients, and appropriate treatment is important for improving their outcomes. Inorganic phosphate, fibroblast growth factor 23, parathyroid hormone, and calciprotein particles are markers for critical components and effectors of CKD-MBD, and higher circulating levels of these markers are linked to cardiovascular diseases. In this short review, we focus on the pathogenesis and management of CKD-MBD in CKD patients, especially those on dialysis therapy, and discuss the prospects for improving the management in CKD patients, including those on dialysis.\",\"PeriodicalId\":74038,\"journal\":{\"name\":\"Kidney and dialysis\",\"volume\":\"21 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kidney and dialysis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/kidneydial3010004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney and dialysis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/kidneydial3010004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

慢性肾脏-矿物质和骨骼疾病(CKD-MBD)是一种全身性疾病,增加了透析患者发病率和死亡率的风险。CKD-MBD在透析患者中非常普遍,适当的治疗对于改善其预后非常重要。无机磷酸盐、成纤维细胞生长因子23、甲状旁腺激素和钙蛋白颗粒是CKD-MBD的关键成分和效应物的标志物,这些标志物的高循环水平与心血管疾病有关。在这篇简短的综述中,我们将重点介绍CKD患者,特别是透析治疗的CKD- mbd的发病机制和管理,并讨论改善CKD患者(包括透析治疗的CKD患者)管理的前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Chronic Kidney Disease—Mineral and Bone Disorder (CKD-MBD), from Bench to Bedside
Chronic kidney disease—mineral and bone disorder (CKD-MBD) is a systemic disorder that increases the risk of morbidity and mortality in dialysis patients. CKD-MBD is highly prevalent in dialysis patients, and appropriate treatment is important for improving their outcomes. Inorganic phosphate, fibroblast growth factor 23, parathyroid hormone, and calciprotein particles are markers for critical components and effectors of CKD-MBD, and higher circulating levels of these markers are linked to cardiovascular diseases. In this short review, we focus on the pathogenesis and management of CKD-MBD in CKD patients, especially those on dialysis therapy, and discuss the prospects for improving the management in CKD patients, including those on dialysis.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信